Loading...
LHCG logo

LHC Group, Inc.NasdaqGS:LHCG Rapporto sulle azioni

Cap. di mercato US$5.3b
Prezzo delle azioni
n/a
US$170
n/dsconto intrinseco
1Y32.1%
7D0.6%
1D
Valore del portafoglio
​
Vista

LHC Group, Inc.

Report azionario NasdaqGS:LHCG

Capitalizzazione di mercato: US$5.3b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LHC Group (LHCG) Panoramica del titolo

LHC Group, Inc., a health care provider, specializes in the post-acute continuum of care primarily for Medicare beneficiaries in the United States. Maggiori dettagli

LHCG analisi fondamentale
Punteggio fiocco di neve
Valutazione0/6
Crescita futura4/6
Prestazioni passate2/6
Salute finanziaria2/6
Dividendi0/6

Premi

Si prevede che gli utili cresceranno del 37.23% all'anno

Analisi del rischio

Il debito non è ben coperto dal flusso di cassa operativo

I margini di profitto (1.7%) sono inferiori rispetto allo scorso anno (5.2%)


LHCG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di LHC Group, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per LHC Group
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$169.81
Massimo di 52 settimaneUS$169.84
Minimo di 52 settimaneUS$115.32
Beta0.42
Variazione di 1 mese3.76%
Variazione a 3 mesi0.91%
Variazione di 1 anno32.12%
Variazione a 3 anni30.61%
Variazione a 5 anni178.06%
Variazione dall'IPO893.04%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Aug 03

LHC Group GAAP EPS of $0.35 misses by $0.95, revenue of $576.2M misses by $29.82M

LHC Group press release (NASDAQ:LHCG): Q2 GAAP EPS of $0.35 misses by $0.95. Revenue of $576.2M (+5.6% Y/Y) misses by $29.82M.
Seeking Alpha • Jul 19

LHC Group: UnitedHealth Merger Is Worth Playing

UnitedHealth’s ongoing acquisition of LHC Group is an interesting merger arbitrage setup, potentially offering an annualized return of 10%. The spread has recently widened as the transaction has attracted the FTC’s attention. The merger still seems likely to close - both companies have a low overlap, the home healthcare market is highly fragmented and the Humana-Kindred merger is a closely comparable transaction. The main risks are antitrust concerns over vertical integration and legal challenges to UnitedHealth’s ongoing merger with Change Healthcare. This is one of the ongoing large-cap merger arbitrage cases where the spread has recently widened. Healthcare and insurance giant UnitedHealth Group (UNH) is buying in-home healthcare company LHC Group (LHCG) at $170 per share. Board/shareholder approvals are already in-the-pocket. The only remaining hurdle is antitrust approval. Until recently, the market was not pricing in any regulatory risk as the spread was around 2%. In June, however, the merger received a second information request from the FTC. Since the news, the spread has jumped and is currently at 5%. In early July, rumors appeared that the FTC’s probe is focused on workers’ pay. Regulatory investigation is currently ongoing and the FTC will have 30 days to finish the review once the companies submit all the required information. Red dot represents FTC’s second request date. Yellow dot is where rumors appeared that FTC’s request is focused on labor pay. FTC’s inquiry comes in light of several industry developments. Firstly, UNH’s other ongoing $13bn merger with Change Healthcare (CHNG) has received pushback from the DoJ. The trial is set for August. However, CHNG operates in a different industry (medical billing software) than LHCG and the UHN-CHNG transaction has a much higher business overlap compared to UNH-LHCG merger. Secondly, since Joe Biden’s executive order on promoting competition in 2021, antitrust regulators have been putting increasing attention on healthcare mergers, highlighting impact on workers’ wages and the degree of vertical integration. These two concerns could be at play in the LHCG-UNH transaction. Also, as of May, the FTC has shifted to a majority-democratic commission, possibly pointing to tighter regulatory scrutiny. Despite these risks, I see several reasons why the LHCG merger is likely to receive regulatory clearance: UNH and LHCG have a low service overlap. The home healthcare market is highly fragmented. The Kindred-Humana merger is a comparable transaction in the home healthcare space. Recent FTC ruling history suggests that healthcare mergers are blocked due to geographical overlap/dominant market shares - largely not applicable to UNH-LHCG. Moreover, seemingly no mergers were blocked solely on labor pay grounds. Let’s go through these one-by-one. Limited Business Overlap LHCG operates in the post-acute healthcare market. The primary focus is on home-based healthcare services which have historically made a lion’s share of revenues at ~80%. This includes two reportable segments - home health (~70%) and home-/community-based care (~10%). The company operates home nursing agencies through which it provides post-acute nursing, medically-oriented social services and therapy. Other segments (~20% of revenues) are hospices, facility-based healthcare services and other healthcare businesses. Meanwhile, UNH is a vertically-integrated multinational company - it runs both health insurance (UnitedHealthcare) and health services (Optum) businesses. The Optum arm provides a continuum of healthcare services, including primary care, virtual care, behavioral health and ambulatory surgery. Even so, the company’s presence in the post-acute in-home care market has been limited. Apparently, ever since the pandemic, UNH has sought to expand the segment. Still, some overlap with LHCG remains - UNH launched its own service HouseCalls as well as acquired start-ups Landmark Health and naviHealth. HouseCalls in an annual in-home medical assessment and not a post-acute care service. Having said that, the number of patient visits in 2021 were at ~2.1m compared to 12m+ patient encounters at LHCG, though the latter include hospice patients. NaviHealth is a software business. The company operates a platform which helps hospital systems and healthcare providers manage clinical decision-making and track patient data. It should be noted that the focus is also on post-acute healthcare services. Landmark Health provides in-home care, however, the focus is exclusively on the sickest and most complicated patients. Services are offered in addition to regular primary care providers, such as LHCG. As of 2019, the number of annual visits was at 400k. Home-Care Market The in-home care market in the US is highly fragmented. To illustrate this, the largest market share captured by Kindred at Home (not publicly-listed) in recent years has been stable at only around 6% while other largest peers (Amedisys and Encompass) have occupied only ~4%-~5%. Company LHCG AMED EHC Kindred at Home Market Cap 5.0 4.1 4.9 Enterprise Value 5.8 4.5 8.0 FY2021 Home Care Revenues ($bn) 1.6 1.4 0.9 Market Share 4.4% 5.0% 3.9% 6.0% Sources: Company filings and HealthCare Appraisers. LexisNexis Visually, LHCG (top-right) appears to cover similar geographies as the largest peers Kindred, Amedisys and Encompass: AMED 8-K Filing, LHCG Investor Presentation, EHC Investor Reference Book, Kindred Healthcare Investor Presentation (Kindred acquired Gentiva in 2015) Looking more specifically, LHCG’s share of the number of home care agencies in several states is significant at ~70% in Mississippi and ~50% in Kentucky. However, these areas have relatively low numbers of total home care providers. Plus, total agency number includes only Medicare-registered providers whose count stands at ~11k compared to a rough estimate of ~35k+ including non-licensed agencies. With this in mind, the merger is unlikely to result in UNH obtaining any alarming market power other than in several specific geographies where divestitures, if needed, could be reasonable to expect. This makes any antitrust pushback very unlikely.
Seeking Alpha • Jul 06

FTC second request in LHC Group/UnitedHealth said to probe pay, labor market

The FTC's second request into UnitedHealth's (NYSE:UNH) planned $5.4 billion purchase of LHC Group (NASDAQ:LHCG) is said to be centered on workers' pay in the home healthcare space. The companies received a second request early last month that was unexpected, according to a Dealreporter item, which cited sources familiar. Kindred Healthcare's sale to Apollo Global also received a second request from the FTC. The FTC is said to be looking at how pay in the healthcare space and how minimum wage workers have trouble bargaining for higher wages, according to the report. UnitedHealth (UNG) agreed to buy home health business LHC Group for $170/share in late March.

Rendimenti per gli azionisti

LHCGUS HealthcareUS Mercato
7D0.6%-1.3%1.5%
1Y32.1%12.4%28.6%

Ritorno vs Industria: LHCG ha superato il US Healthcare che ha restituito 12.4 % nell'ultimo anno.

Rendimento vs Mercato: LHCG ha superato il mercato US che ha restituito 28.6 % nell'ultimo anno.

Volatilità dei prezzi

Is LHCG's price volatile compared to industry and market?
LHCG volatility
LHCG Average Weekly Movement2.1%
Healthcare Industry Average Movement7.3%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Prezzo delle azioni stabile: LHCG non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 2% ) di LHCG è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
199423,000Keith Myerswww.lhcgroup.com

LHC Group, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di LHC Group con la sua capitalizzazione di mercato?
LHCG statistiche fondamentali
Capitalizzazione di mercatoUS$5.29b
Utili (TTM)US$39.87m
Ricavi(TTM)US$2.28b
132.7x
Rapporto P/E
2.3x
Rapporto P/S

LHCG è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
LHCG Conto economico (TTM)
RicaviUS$2.28b
Costo del fatturatoUS$1.40b
Profitto lordoUS$883.61m
Altre speseUS$843.74m
UtiliUS$39.87m

Ultimi utili riportati

Dec 31, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)1.28
Margine lordo38.71%
Margine di profitto netto1.75%
Rapporto debito/patrimonio netto43.0%

Come si è comportato LHCG nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2023/02/23 22:09
Prezzo dell'azione a fine giornata2023/02/21 00:00
Utili2022/12/31
Utili annuali2022/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

LHC Group, Inc. è coperta da 21 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Matthew GillmorBaird
Steven ValiquetteBarclays
Sarah JamesBarclays